Home > Insider Trading > Filing (0001140361-25-022713)

Filing Details

Accession Number:: 0001140361-25-022713
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-06-16 21:00:32
Reporting Period:: 2025-06-12

Filing Date:: 2025-06-16
Accepted Time:: 2025-06-16 21:00:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1368514	Adma Biologics Inc.	ADMA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1250195	Steve Elms	C/O Aisling Capital Management Lp 489 Fifth Avenue, 10Th Floor New York NY 10017		No	No	No	No

Transaction Summary

Sold:	425,621 shares	Avg. Price: $20.74	Total Value: $8,829,333.47
Number of Shares After Transactions:	87,330 shares

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-06-12	92,941	$21.69	2,031,730	No	4	S	Indirect	See footnote
Common Stock	Acquisiton	2025-06-13	9,000	$5.96	96,330	No	4	M	Direct
Common Stock	Acquisiton	2025-06-13	10,000	$5.00	106,330	No	4	M	Direct
Common Stock	Acquisiton	2025-06-13	53,837	$3.66	160,167	No	4	M	Direct
Common Stock	Acquisiton	2025-06-13	17,500	$4.91	177,667	No	4	M	Direct
Common Stock	Acquisiton	2025-06-13	30,000	$3.89	207,667	No	4	M	Direct
Common Stock	Acquisiton	2025-06-13	15,000	$2.92	222,667	No	4	M	Direct
Common Stock	Acquisiton	2025-06-13	55,000	$2.35	277,667	No	4	M	Direct
Common Stock	Acquisiton	2025-06-13	53,172	$1.67	330,839	No	4	M	Direct
Common Stock	Acquisiton	2025-06-13	51,630	$3.35	382,469	No	4	M	Direct
Common Stock	Acquisiton	2025-06-13	37,541	$5.40	420,010	No	4	M	Direct
Common Stock	Disposition	2025-06-13	137,931	$20.82	282,079	No	4	S	Direct
Common Stock	Disposition	2025-06-16	194,749	$20.24	87,330	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	9,000	$0.00	9,000	$5.96
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	10,000	$0.00	10,000	$5.00
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	53,837	$0.00	53,837	$3.66
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	17,500	$0.00	17,500	$4.91
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	30,000	$0.00	30,000	$3.89
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	15,000	$0.00	15,000	$2.92
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	55,000	$0.00	55,000	$2.35
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	53,172	$0.00	53,172	$1.67
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	51,630	$0.00	51,630	$3.35
Common Stock	Stock Option (Right to Buy)	Disposition	2025-06-13	37,541	$0.00	37,541	$5.40

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2026-01-28	No	4	M	Direct
2027-02-14	No	4	M	Direct
2027-06-06	No	4	M	Direct
2028-06-22	No	4	M	Direct
2029-03-13	No	4	M	Direct
2030-02-28	No	4	M	Direct
2031-02-25	No	4	M	Direct
2032-03-07	No	4	M	Direct
2033-03-06	No	4	M	Direct
2034-02-26	No	4	M	Direct

Footnotes

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.37 to $22.17, inclusive. The reporting person undertakes to provide to ADMA Biologics, Inc. (the "Issuer"), any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (5).
These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest therein.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.39, inclusive.
Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 271,190 shares of common stock owned by the reporting person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.40, inclusive.
Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 76,441 shares of common stock owned by the reporting person.
These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.
These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.